Skip to main content
Premium Trial:

Request an Annual Quote

BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection

NEW-YORK ─ BforCure recently announced it has raised €2 million ($2.3 million) from ID-Solutions to adapt its fast in vitro diagnostic PCR platform Chronos Dx to detect cancers.

Chronos Dx leverages BforCure's Fastgene technology to enable a PCR test in less than 15 minutes, the firm said.

The Paris-based point-of-care testing firm said that in the short term it aims to offer a menu of syndromic panels, and in the coming years enter cancer diagnostic testing through its partnership with ID-Solutions, a French biotech company that specializes in oncology diagnostics.

According to BforCure's website, the firm develops platforms based on microfluidics technology for numerous fields including medical diagnostics, defense and security, the food industry, and environmental protection. Fastgene technology reduces PCR cycles from minutes to seconds, the firm added.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.